title: The appropriate omalizumab patient.
abstract: Allergy is a significant component in many asthma patients. Omalizumab is a monoclonal anti-immunoglobulin E antibody for the treatment of allergic asthma. Clinical trials have shown that omalizumab treatment is associated with improved symptom control and reduced inhaled corticosteroid doses, resulting in fewer exacerbations and reduced utilization of resources. Omalizumab therapy may benefit patients who remain uncontrolled or who cannot tolerate standard therapy.
authors.affiliation: Beth Thalheim Asthma Center, North Shore University Hospital, Manhasset, NY, USA. jpkarpel@aol.com
authors.forename: Jill
authors.initials: J
authors.lastname: Karpel
authors.forename: Donald A
authors.initials: DA
authors.lastname: Bukstein
authors.forename: Robert
authors.initials: R
authors.lastname: LoNigro
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D000069444:Omalizumab; D014481:United States
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab